ניאספן 750 מ"ג טבליות מצופות בשחרור ממושך

Country: ইস্রায়েল

ভাষা: হিব্রু

সূত্র: Ministry of Health

সক্রিয় উপাদান:

NIACIN 750 MG

থেকে পাওয়া:

ABBOTT MEDICAL LABORATORIES LTD

এটিসি কোড:

C04AC01

ফার্মাসিউটিকাল ফর্ম:

FILM COATED TABLETS - EXTENDED RELEASE

প্রশাসন রুট:

PER OS

Manufactured by:

ABBOTT LABORATORIES , USA

Therapeutic group:

NICOTINIC ACID

থেরাপিউটিক ইঙ্গিত:

Therapy with lipid-altering agents should be only one component of multiple risk factor intervention in individuals at significantly increased risk for atherosclerotic vascular disease due to hyperlipidemia. Niacin therapy is indicated as an adjunct to diet when the response to a diet restricted in saturated fat and cholesterol and other nonpharmacologic measures alone has been inadequate. 1.NIASPAN is indicated to reduce elevated TC, LDL-C, Apo B and TG levels, and to increase HDL-C in patients with primary hyperlipidemia and mixed dyslipidemia. 2.NIASPAN in combination with simvastatin or lovastatin is indicated for the treatment of primary hyperlipidemia and mixed dyslipidemia when treatment with NIASPAN, simvastatin, or lovastatin monotherapy is considered inadequate. 3.In patients with a history of myocardial infarction and hyperlipidemia, niacin is indicated to reduce the risk of recurrent nonfatal myocardial infarction. 4.In patients with a history of coronary artery disease (CAD) and hyperlipidemia, n

অনুমোদন তারিখ:

2012-08-01